Quick Answer
Camp4 Therapeutics Corp reported Diluted EPS of $2.65 per share (loss) for fiscal year 2025.
Camp4 Therapeutics Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.65 | +76.0% |
| 2024 | -$11.04 | +91.2% |
| 2023 | -$124.80 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.55 | +97.7% | +11.3% |
| June 30, 2025 | -$0.62 | +97.6% | +0.0% |
| March 31, 2025 | -$0.62 | +97.7% | +97.4% |
| September 30, 2024 | -$24.19 | +17.2% | +7.0% |
| June 30, 2024 | -$26.00 | — | +2.1% |
| March 31, 2024 | -$26.57 | — | +9.0% |
| September 30, 2023 | -$29.21 | — | — |
- Camp4 Therapeutics Corp showed an increase of +76.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Camp4 Therapeutics Corp’s diluted eps has grown by 97.9% (from $124.80 per share (loss) to $2.65 per share (loss)).
- The most recent figure is from Camp4 Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: